Melhores Linfoma não-Hodgkin médicos em Turquia - TOP-24 médicos

O conteúdo segue a Política Editorial da Bookimed e foi revisado por

Fahad Mawlood

Bülent Karagöz

  • 4.6 Excelente 507 avaliações
  • 32 anos de experiência
  • Turquia, Istambul, Anadolu Medical Center
  • Autor de mais de 40 publicações revisadas por pares em biologia/imunologia de tumores e terapia sistémica (imunoterapia e terapia direcionada); membro da Associação Turca de Oncologia Médica e da Sociedade Europeia de Cabeça e Pescoço.

    Por que os pacientes escolhem o Dr. Bülent Karagöz:

    • Tratamento baseado em protocolos dos EUA através da colaboração estratégica do Centro Médico de Anadolu com uma instituição líder nos EUA — Johns Hopkins Medicine.
    • Mais de 40 publicações científicas em biologia/imunologia de tumores e terapia sistémica (imunoterapia e terapia direcionada).
    • Ex-chefe de departamento (GATA) e professor/cadeira de departamento (Universidade Okan, Turquia) — liderança e experiência clínica em grandes centros.
    • Trata tumores sólidos (por exemplo, mama, pulmão, colorretal), aplicando regimes modernos orientados pela biologia do tumor.
    • Centro Médico de Anadolu possui designação ESMO e acreditação JCI — significando que o médico trata de acordo com protocolos internacionais, dentro de uma equipa multidisciplinar, com supervisão rigorosa de segurança.
  • Leia mais
Transplante alogénico de medula óssea de dador não relacionado
57 256 € - 57 256 €
Quimioterapia
1431 € - 5639 €
Transplante alogénico de medula óssea de dador relacionado
43 376 € - 43 376 €
Info

Zafer Gulbas

  • 4.6 Excelente 507 avaliações
  • 48 anos de experiência
  • acreditações:
  • Turquia, Istambul, Anadolu Medical Center
  • Professor Zafer Gülbaş — hematologista-oncologista, fundador e diretor do Centro de Transplante de Medula Óssea no Centro Médico Anadolu, que está entre os maiores da Europa.

    Por que os pacientes escolhem e confiam no Dr. Gülbaş:

    • Construiu o Centro de Transplante de Medula Óssea do Anadolu do zero; o centro já realizou mais de 3 000 transplantes (desde 2010).
    • Taxa de sucesso de 81% para transplantes autólogos — um número elevado de acordo com os dados do centro.
    • Formação e prática internacionais em instituições líderes — Hadassah (Israel), Fred Hutch e MD Anderson (EUA), Princess Margaret (Canadá).
    • Mais de 260 publicações científicas e mais de 5 000 citações — destacando a significativa contribuição do professor para a área de transplantes.
    • O Centro Médico Anadolu é parceiro oficial da Johns Hopkins Medicine International, garantindo acesso a protocolos internacionais, comitês multidisciplinares e supervisão de qualidade.
    • Gerencia os casos mais complexos: leucemias, linfomas, anemia aplástica e coagulopatias (distúrbios de coagulação).
  • Leia mais
Transplante alogénico de medula óssea de dador não relacionado
57 256 € - 57 256 €
Quimioterapia
1431 € - 5639 €
Transplante alogénico de medula óssea de dador relacionado
43 376 € - 43 376 €
Info

Yesim Yildirim

  • 4.6 Excelente 507 avaliações
  • 21 anos de experiência
  • acreditações:
  • Turquia, Istambul, Anadolu Medical Center
  • Prof. Yeşim (Yesim) Yıldırım — Oncologista Médica no Centro Médico Anadolu (desde 2011). Especialista certificado pela ESMO, Professora desde 2021, autora de mais de 80 publicações científicas. Formada em centros de excelência — Rambam (Israel) e Mount Vernon (Reino Unido). Trata cânceres de mama, pulmão e gastrointestinais (GI), além de melanoma e sarcomas; utiliza imunoterapia e terapia direcionada.

    Por que os pacientes escolhem a Dr.ª Yeşim Yıldırım:

    • Mais de 20 anos de prática clínica; Professora de Oncologia Médica desde 2021.
    • Mais de 80 publicações revisadas por pares em biologia tumoral, imunoterapia e terapia direcionada — planos de tratamento baseados em evidências atualizadas.
    • Certificação ESMO — da principal sociedade europeia de oncologia — confirma alta qualificação e formação contínua de acordo com os padrões internacionais.
  • Leia mais
Transplante alogénico de medula óssea de dador não relacionado
57 256 € - 57 256 €
Quimioterapia
1431 € - 5639 €
Transplante alogénico de medula óssea de dador relacionado
43 376 € - 43 376 €
Info

Savash Kansoy

  • 4.6 Excelente 507 avaliações
  • 47 anos de experiência
  • Turquia, Istambul, Anadolu Medical Center
  • Formação

    • Faculdade de Medicina de Ege 1978
    • Especialização em Pediatria 1982
    • Subespecialidade em Oncologia Pediátrica 2002 (Faculdade de Medicina EU)
    • Hematologia e Oncologia Pediátrica 2012 (Faculdade de Medicina EU)
    • Chefe Adjunto de Clínica 1988 Tepecik EAH
    • Chefe de Clínica 1993 Tepecik EAH
    • Professor Associado 1995
    • Professoria 2002
    • Faculdade de Medicina da Universidade de Ege, membro do corpo docente 1998 – 2022
    • Departamento de Pediatria da Faculdade de Medicina da UE 2009-2018
    • Membro do Conselho de Planejamento e Coordenação de Educação Tepecik (1993-1998)
    • Presidente do Comitê de Ética do SSI Hospital de Tepecik (1996-1998)
    • Sociedade Turca de Hematologia Pediátrica "Co-Presidente do Grupo de Trabalho em Transplante de Medula Óssea" (2002-2006)
    • Sociedade Turca de Hematologia Pediátrica "Grupo de Trabalho em Transplante de Medula Óssea" (2006-2008)
    • Sociedade Turca de Hematologia Pediátrica - Responsável pelo Sistema de Registro de Dados "Online" de Transplante de Medula Óssea 2007-presente.
    • Presidente da Comissão de Medicina Regenerativa e Células-Tronco da Universidade de Ege, 2011-2021

    Filiações Institucionais

    • Associação Médica Turca Ramo de Izmir e Kocaeli
    • Associação Pediátrica Nacional Turca - İzmir
    • Grupo Europeu para Transplante de Medula Óssea (EBMT); a Unidade de Transplante de Medula Óssea Pediátrica da Universidade de Ege foi credenciada pelo Grupo Europeu para Transplante de Medula Óssea (EBMT) em junho de 2007.
    • Sociedade Turca de Hematologia Pediátrica - Membro do Conselho por dois mandatos (2005-2009)
    • Sociedade Turca de Hematologia - Membro do Conselho por dois mandatos (2001/2005)
    • Associação de Oncologia Pediátrica da Turquia
    • Fundação de Transplante de Medula Óssea (KITVAK) Membro do Conselho de Curadores

    Unidades que ele fundou                        

    1- Clínica de Oncologia Pediátrica do SSI Hospital de Tepecik (1990) 
    2- Unidade de Transplante de Medula Óssea Pediátrica do SSI Hospital de Tepecik (1992) 
    3- Unidade de Transplante de Medula Óssea Pediátrica da Faculdade de Medicina da UE (1998) 
    4- FUNDADOR do JOURNAL OF PEDIATRIC RESEARCH, 2014; foi feita a aplicação SCI em 2022. 

    Unidades de Transplante que ele contribuiu para o estabelecimento de                        

    1. Unidade de Transplante de Medula Óssea Pediátrica do İzmir BUÇH EAH (2019) 
    2. Unidade de Transplante de Medula Óssea Pediátrica do Ümraniye EAH (2020) 
    3. Unidade de Transplante de Medula Óssea Pediátrica do Kanuni Sultan Süleyman EAH (2020) (Transferida para Çam Sakura EAH)

    Prémios

    • Parâmetros trombóticos em pacientes com transplante de células-tronco de medula óssea, Congresso de Hematologia Pediátrica, Trabzon 2003
    • Antígeno CD133 em Células-Tronco: Congresso de Hematologia Pediátrica 2005. Prémio de pesquisa
    • O papel dos Receptores Toll-like em pacientes neutropênicos febris, Prémio de melhor poster. Congresso de Hematologia Turca 2008, Çeşme-İzmir
    • Atividade nacional de transplante de células-tronco pediátrico- Apresentação oral segundo prémio, Congresso de Transplante de Células-Tronco da Sociedade de Hematologia Turca, 2022, Antalya

    Publicações

    Kansoy S. "Transplante de Medula Óssea e Células-Tronco Saúde Infantil e Doenças, 1ª edição, Casa de Impressão da Faculdade de Medicina da UE, 1999, Izmir

    Kansoy S. Transplante de Medula Óssea na Talassemia Major III. Livro dos Dias de Talassemia do Egeu, 2000, Izmir

    Kansoy S. Padrões da Pediatria KIT na Turquia. Leucemias Agudas da Infância, Antalya 2000: 73-5

    Kansoy S. Efeitos tardios em crianças. Edição especial do Jornal de Transplante de Medula Óssea Clínicas Turcas. 2003

    Kansoy S. Aplicações de Células-Tronco em Transplante de Medula Óssea e Células-Tronco. Livro do Curso de Enfermagem Oncológica Pediátrica, İzmir, 2005

    Kansoy S. Sangue do Cordão Umbilical como Fonte de Células-Tronco. Edição Especial de Células-Tronco. Clínicas da Turquia, 2008

    Kansoy S. Transplante de Células-Tronco em Linfomas. Livro de Pediatria Geral, Ed. Prof.Dr.Enver Hasanoglu, 2009

    Kansoy S, Aksoylar S. Transplante de Medula Óssea em Crianças. Pediatria, 2014 e 2017

    Kansoy S. Rabdomiossarcoma. Pediatria, 2014 e 2017

    Kansoy S. Abordagem à criança com câncer de acordo com os achados clínicos. Pediatria, 2014 e 2017 

    11. Çetingül N, S.Kansoy, M.Kantar. Doenças Oncológicas. Pediatria (Ed. A. Cura), 641-672, Casa de Impressão da Universidade de Ege, Izmir, 1999.  (1,05 pontos)

    Kansoy S, M.Kantar. Exame de Cabeça, Face e Olho. Exame Físico Prosético Pediátrico e Informação de Sintomas (Ed. A.Cura)

    Kantar M. Problemas de Emergência Metabólica em Oncologia. Emergências Oncológicas e Cuidados de Apoio na Infância (Ed. N. Çetingül, S. Kansoy), 15-24, Meta Basım, Izmir, 2003. 

    Transplantes de Sangue do Cordão Umbilical na Turquia. HEMATOLOGISTA, 2016

    Kansoy S. Tumores do Sistema Nervoso Central em Crianças Pediatria, 2014 e 2017

    Leucemia Mieloblástica Aguda em Crianças e seu Tratamento. Livro Textbook de Oncologia Pediátrica, Turco de Poplack, 2020

    Atividade nacional de transplante de células-tronco pediátrico, 2020

    Indicações de transplante de células-tronco na infância, Clínicas da Turquia - Livro Internacional 2020

    Além dos estudos e artigos em revistas internacionais publicadas em grande número, ele está envolvido em estudos multicêntricos internacionais em algumas revistas com alto valor de impacto.

  • Leia mais
Transplante alogénico de medula óssea de dador não relacionado
57 256 € - 57 256 €
Quimioterapia
1431 € - 5639 €
Transplante alogénico de medula óssea de dador relacionado
43 376 € - 43 376 €
Info

Sebnem Izmir Guner

  • 4.5 Bom 193 avaliações
  • 32 anos de experiência
  • Turquia, Istambul, Hisar Hospital Intercontinental
  • Prof. Dr. Şebnem İzmir Güner was born in 1970 in Istanbul and took her first steps in her medical career at Istanbul University Faculty of Medicine. Successfully completing her undergraduate and medical education here between 1987-1993, Güner received her internal medicine specialty training at Istanbul University Cerrahpaşa Faculty of Medicine from 1995 to 2000. Deepening her interest in hematology, Prof. Dr. Güner completed her hematology subspecialty training at Cerrahpaşa Faculty of Medicine again between 2003-2006, solidifying her expertise in this field.
    Prof. Dr. Güner’s professional journey began as an internal medicine specialist at Istanbul Education and Research Hospital from 2000 to 2003. She established the Hematology Clinic at the same hospital from 2006 to 2010 and served as the responsible physician. Here, she developed innovative approaches in the treatment of patients and made significant contributions to the field of hematology. From 2010 to 2016, she established the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center at Medicalpark Bahçelievler Hospital and served as the responsible physician. During this period, she conducted studies that set national and international standards in the field of hematology.
    Between 2016-2018, Prof. Dr. Güner took on similar roles at Şişli Kolon International Hospital, where she was also the founder and responsible physician of the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center. Güner, who became an associate professor in 2017, obtained her professorship title in 2023. Between 2019-2024, she worked at Memorial Şişli Hospital in the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center.
    Prof. Dr. Şebnem İzmir Güner is recognized for her scientific contributions, with over 19 articles published in international peer-reviewed journals. Additionally, she has over 18 articles published in national peer-reviewed journals and 51 presentations at national scientific meetings that have been published in proceedings books. She has also made a name for herself in the academic world with over 18 presentations at meetings and published in proceedings books. Güner, who has held positions on the boards of domestic hematology associations and has active memberships, has crowned her success with more than three awards given at universities and conferences.
    Prof. Dr. Şebnem İzmir Güner, who speaks English and German, is also recognized as an educator. In this capacity, she has contributed to the training of young doctors in the field of hematology, providing education to research assistant doctors and students.
    Prof. Dr. Şebnem İzmir Güner has established a respected place in the field of hematology with her achievements and scientific contributions throughout her professional life, continuing her career as a physician who inspires her patients and colleagues.

    MEDICAL INTERESTS

    • Leukemia
    • Lymphoma
    • Multiple myeloma
    • Bone marrow transplantation
    • Anemia
    • Bleeding and coagulation disorders
    • Hemophilia
  • Leia mais
Quimioterapia
1301 € - 2169 €
Transplante de medula óssea
30 363 € - 52 051 €
Info

Alp Özkan

  • 4.6 Excelente 507 avaliações
  • 25 anos de experiência
  • Turquia, Istambul, Anadolu Medical Center
  • Dr. Alp Özkan is a highly experienced Turkish pediatric oncologist with over 20 years of experience in lymphoma treatment. He has worked in the USA, is a professor at Istanbul University, and has published 5 books on pediatric cancer treatment. He has won the Turkish Scientific Prize in Pediatric Oncology and has authored more than 70 scientific articles.
  • Leia mais
Transplante alogénico de medula óssea de dador não relacionado
57 256 € - 57 256 €
Quimioterapia
1431 € - 5639 €
Transplante alogénico de medula óssea de dador relacionado
43 376 € - 43 376 €
Info

Toluy Ozgumus

  • 4.5 Bom 193 avaliações
  • 8 anos de experiência
  • Turquia, Istambul, Hisar Hospital Intercontinental
  • Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.

    He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as bone marrow transplantation.

     

    MEDICAL INTERESTS 

    Clotting Disorders (Thrombophilia)

    Bleeding Disorders

    Myeloproliferative Diseases

    Anemias (Anemia)

    Acute and Chronic Leukemias

    lymphomas

    Bone marrow transplantation

  • Leia mais
Quimioterapia
1301 € - 2169 €
Transplante de medula óssea
30 363 € - 52 051 €
Info

Oguzhan Babacan

  • 4.5 Bom 193 avaliações
  • 27 anos de experiência
  • Turquia, Istambul, Hisar Hospital Intercontinental
  • Assoc. Prof. Dr. Oğuzhan BABACAN completed his undergraduate, specialty and sub-specialty education at GATA Military Medical Faculty/Ankara. After becoming a specialist in Pediatrics, he worked in the field of Social Pediatrics for two years, where Healthy Baby Monitoring and vaccine follow-up were carried out. Then, she completed her subspecialty training in Pediatric Hematology and Oncology and continued her studies in the field of pediatric blood and cancer diseases. In addition to the treatment of children suffering from leukemia, lymphoma, solid tumors and other blood diseases, she has been working in the Bone Marrow Transplantation (Transplant) Unit for 13 years in Allogeneic (unrelated and intrafamilial), Autologous (from the patient himself) and Haploidentical (partially HLA compatible) hematopoietic stem cell transplantation. In 2018, he received the title of Associate Professor in the field of Pediatric Hematology and Oncology Science/Art.

     

    MEDICAL AREAS OF INTEREST

    Healthy baby follow-up and vaccinations

    Lymph node enlargement

    Pediatric patients with anemia (anemia)

    Leukemia

    Lymphoma

    Bone Marrow Transplant

    ITP

    Thalassemias

    Hemophiliacs

    Solid tumors

    Hemangioma

    Childhood blood disorders

    Children with frequent infections

    Fever of unknown origin

    Malnutrition in children

  • Leia mais
Quimioterapia
1301 € - 2169 €
Transplante de medula óssea
30 363 € - 52 051 €
Info

Omur Gokmen Sevindik

  • 5 Excelente 47 avaliações
  • 11 anos de experiência
  • Turquia, Istambul, Istanbul Florence Nightingale Hospital
  • Education:

    2015

    Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

     

    2010

    Dokuz Eylül University, Medical Faculty, Internal Medicine 

     

    2005

    Hacettepe University, Medical Faculty,

     

    Experience:

     

    2024 – 

    Istanbul Florence Nightingale Hospital

     

    2017 – 2024

    Bağcılar Medipol University Hospital

     

    2017 – 2017

    Fırat University

     

    2015 - 2017

    Fırat University

     

    2014 - 2015

    Mayo Clinic

     

    Publications:

    18 Articles Published in International Peer-Reviewed Journals

    26 Abstracts and Books Presented at International Scientific Conferences

    7 Articles Published in National Peer-Reviewed Journals

    51 Abstracts Presented at National Scientific Conferences

  • Leia mais
Consulta médica
Preço sob consulta
Info

Mustafa Serkan Alemdar

  • 4.5 Bom 6 avaliações
  • 19 anos de experiência
  • Turquia, Antália, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Leia mais
Transplante de medula óssea
13 013 € - 17 350 €
Info

Deniz Gören

  • 4.7 Excelente 343 avaliações
  • 10 anos de experiência
  • Turquia, Istambul, Memorial Şişli Hospital
  •  

    Medical Experience:

    - 2024 - Present: Memorial Şişli Hospital  

     Specialist in Internal Medicine and Hematology / Istanbul

    - 2017 - 2024: Istanbul Florence Nightingale Hospital  

     Specialist in Internal Medicine and Hematology / Istanbul

    - 2015 - 2017: Eskişehir Yunus Emre State Hospital  

     Hematology Specialist - Compulsory Service / Eskişehir

     

    Medical Education:

    - 2020 - 2024: Istanbul Florence Nightingale Hospital  

     Demiroğlu Bilim University, Faculty of Medicine / Istanbul, Turkey

    - 2017 - 2020: Istanbul Florence Nightingale Hospital  

     Demiroğlu Bilim University, Faculty of Medicine / Istanbul, Turkey

    - 2011 - 2015: Eskişehir Osmangazi University, Faculty of Medicine, Department of Hematology / Eskişehir, Turkey

    - 2009 - 2011: Harvard University, Faculty of Medicine / Boston, USA

    - 2000 - 2008: Ankara University, Faculty of Medicine / Ankara, Turkey

    - 1994 - 2000: Ankara University, Faculty of Medicine / Ankara, Turkey

     

    Attended Professional Trainings, Courses, and Conferences:

    - European Society for Blood and Marrow Transplantation, 3rd EBMT International Transplant Course, Barcelona, Course, 07.09.2018-09.09.2018 (International)

    - Turkish Academy of Blood Science, Lymphoma Masterclass, Istanbul, Course, 01.09.2016-01.03.2017 (National)

    - Advanced Life Support Course, Istanbul

     

    Membership in Professional Associations:

    - European Society for Blood and Marrow Transplantation

    - Turkish Academy of Blood Science

    - Advanced Life Support Course

  • Leia mais
Transplante alogénico de medula óssea de dador não relacionado
67 232 € - 67 232 €
Transplante de medula óssea
44 677 € - 60 292 €
Info

Necdet Uskent

  • 4.6 Excelente 507 avaliações
  • 45 anos de experiência
  • Turquia, Istambul, Anadolu Medical Center
  • Professor of Oncology and Hematology

Transplante alogénico de medula óssea de dador não relacionado
57 256 € - 57 256 €
Quimioterapia
1431 € - 5639 €
Transplante alogénico de medula óssea de dador relacionado
43 376 € - 43 376 €
Info

Mehmet Hilmi Dogu

  • 4.5 Bom 234 avaliações
  • 35 anos de experiência
  • Turquia, Istambul, Liv Hospital Ulus
  • Medical Fields of Interest: 

    Chronic Leukemia (Chronic Lymphocytes Leukemia/ Chronic Myeloid Leukemia) 

    Chronic Myeloproliferative Diseases (Polistemia Vera, Essential Thrombocytosis, Myelofibrosis etc.) 

    Lymphoma (Hodgkin’s and Non-Hodgkin’s) 

    Multiple Myeloma 

    Education: 

    Ege University Faculty of Medicine Medical Doctor 1999 - 2005 

    Pamukkale University Specialist in Internal Medicine 2006 - 2011 

    Pamukkale University Hematologist 2011 - 2014 

    ESCCA Summer School On Cytometry/PRAGUE (May 2014) 

    Istanbul Training and Research Hospital Hematology Clinic Associate Professor 2018 

    Experience: 

    Selçuk University Faculty of Medicine Hospital 2015 

    Pamukkale University Internal Medicine Residency Training 2016 - 2011 

    Denizli Sarayköy State Hospital 2011 - 2011 

    Pamukkale University Hematology Minor Residency Training 2011 - 2014 

    Istanbul Training and Research Hospital Hematology Clinic Specialist Doctor 2015 - 2020 

    Istanbul Training and Research Hospital Hematology Clinic Responsible Authority 2015 - 2020 

    Istanbul Training and Research Hospital Hematology Clinic Responsible Authority/ Lecturer 2019 - 2020 

    Istanbul Başakşehir Çam and Şakura City Hospital Hematology Clinic Lecturer 2020 - 2020

    Liv Hospital Ulus 2020-

    Memberships: 

    Turkish Society of Hematology 

    The Society of Hematological Education and Research (Member of The Board of Directors

    Publications:

    32 articles published in international peer-reviewed journals 

    12 cases published in international peer-reviewed journals 

    11 articles published in national peer-reviewed journals 

    5 cases published in national peer-reviewed journals

  • Leia mais
Transplante alogénico de medula óssea de dador relacionado
74 606 € - 74 606 €
Transplante autólogo de medula óssea
26 025 € - 26 025 €
Info

Ayhan Gulsan

  • 4.9 Excelente 53 avaliações
  • 24 anos de experiência
  • Turquia, Istambul, Valued Med Hub Hospitals
  • Education and Expertise

    Ankara University Faculty of Medicine - Medical Education

    Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization

    Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty

    Duke University Bone Marrow Transplantation Center - Stem Cell Transplantation Training

    Fred Hutchinson Cancer Research Center Seattle - Stem Cell Transplant Training

     

    Experience

    Duke University-Durham North Carolina Bone marrow transplantation program 2001, cord blood transplant

    Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant

    Founder and manager of Gazi University Faculty of Medicine Adult Stem Cell Transplant Unit 2003-2014

    Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014

    Gazi University Faculty of Health Sciences Dean (founder) 2008-2012

     

    Professional Memberships

    Turkish Hematology Association





    Bilimsel Yayınları

    1.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
        Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
    2.    Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
    3.    Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
    4.    Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201. 
    5.    Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
    6.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
    7.    Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80. 
    8.    van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
    9.    Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90. 
    10.    Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7. 
    11.    Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
    12.    Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40. 
    13.    Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
    14.    Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015  Apr 28.
    15.     Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20. 
    16.    Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
    17.    Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
    18.    Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
    19.    Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
    20.    Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
    21.    Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
    22.    Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
    23.    Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62. 
    24.    Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
    25.    Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318   Pages 323 – 324
    26.    Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
    27.    Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
    28.    Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
    29.    Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
    30.    Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
    31.    Keser I, Suyani E, Aki SZ,  Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
    32.    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.  Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
    33.    Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
    34.    Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
    35.    Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
    36.    Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
    37.    Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
    38.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
    39.    Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
    40.    Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
    41.    Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
    42.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
    43.    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
    44.    Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
    45.    Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
    46.    Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
    47.    Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
    48.    Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
    49.    Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells.J Endocrinol. 2012 Feb;212(2):169-78.
    50.    Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
    51.    Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
    52.    Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
    53.    Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
    54.    Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
    55.    Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
    56.    Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
    57.    Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
    58.    Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
    59.    Ljungman P,  de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
    60.    Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
    61.    Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
    62.    Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
    63.    Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
    64.    Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
    65.    Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
    66.    Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
    67.    Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
    68.    Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
    69.    Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.

  • Leia mais
Quimioterapia
3470 € - 4338 €
Info

Itir Sirinoglu Temiz

  • 5 Excelente 7 avaliações
  • 35 anos de experiência
  • Turquia, Istambul, Liv Hospital Vadistanbul
  • Dr. Itir Sirinoglu Temiz is a Professor of Hematology. She specializes in lymphoma, acute and chronic leukemias, multiple myeloma, thrombocytopenias, thrombosis, anemia, and bone marrow failure. She graduated with honors from Istanbul University Cerrahpaşa Faculty of Medicine. She completed her hematology training at Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital.

    Dr. Sirinoglu Temiz has held key academic and administrative positions. She served as Head of Internal Medicine at IAU Faculty of Medicine. She was also Education and Administrative Manager at SBÜ Bakırköy Dr. Sadi Konuk EAH Hematology Clinic. She has broad experience in adult hematology, stem cell transplantation, and therapeutic apheresis. She currently practices at Liv Hospital.

  • Leia mais
Quimioterapia
2603 € - 3036 €
Info

Serdar Bedii Omay

  • 4.4 Bom 32 avaliações
  • 35 anos de experiência
  • Turquia, Istambul, Emsey Hospital
  • O Prof. Dr. Serdar Bedii Omay é um respeitado hematologista. Ele é especialista em Hematologia e Transplante de Medula Óssea. Graduou-se na Faculdade de Medicina de Hacettepe em 1985. Completou sua formação em Medicina Interna na Universidade de Ege em 1990. Obteve seu doutorado em Hematologia na Escola Médica Mie do Japão em 1995.

    O Dr. Omay publicou 65 artigos científicos, 112 artigos em congressos e 34 apresentações em conferências internacionais. Atuou como professor na Universidade de Ege e na Universidade Técnica de Karadeniz. Também trabalhou como Especialista em Hematologia e Doutor em Hematologia Molecular no Japão. Sua carreira demonstra uma forte especialização e reconhecimento internacional na sua área.

  • Leia mais
Transplante de medula óssea
33 833 € - 85 884 €
Info

Birol Baytan

  • 4.4 Bom 32 avaliações
  • 33 anos de experiência
  • Turquia, Istambul, Emsey Hospital
  • Prof. Dr. Birol Baytan is a respected pediatric hematologist. He focuses on diagnosing and treating childhood cancers, leukemia, anemia, and bleeding disorders. He graduated from Ankara University Medical Faculty in 1992. He completed his specialization at Uludağ University Faculty of Medicine, Department of Child Diseases.

    Prof. Baytan has published 15 articles in international journals. He has presented and published 9 full texts at international scientific meetings. He has contributed to 3 books or book chapters. He has also published 8 articles in local journals. These achievements show his strong academic presence in pediatric hematology.

  • Leia mais
Transplante de medula óssea
33 833 € - 85 884 €
Info

Siret Ratip

  • 4.4 Bom 7 avaliações
  • 32 anos de experiência
  • Turquia, Istambul, Acibadem Altunizade Clinic
  • Dr. Siret Ratip is a hematologist and oncologist with over 25 years of clinical experience. He focuses on internal medicine and hematology. He has worked as an associate professor at respected institutions, including University College Hospital in London.

    Dr. Ratip is a member of the British Hematology Committee and the Hematology Federation of Turkey. He has performed many advanced procedures, such as autologous and allogenic bone marrow transplantation, bone marrow aspiration, and biopsy. He has made important contributions to patient care and research in thalassemia.

  • Leia mais
Quimioterapia para cancro da mama
7374 € - 8675 €
Info

Rafet Eren

  • Novo
  • 18 anos de experiência
  • Turquia, Istambul, Biruni University Hospital
  • Education

    • Undergraduate: Istanbul Faculty of Medicine, Istanbul University, 2007
    • MSc (Internal Medicine Department): Marmara University Faculty of Medicine, 2012
    • PhD (Hematology Clinic): Istanbul Training and Research Hospital, 2018
    • Associate Professor (Hematology Clinic): Prof.Dr.Cemil Tascioglu Training and Research Hospital, 2019

    Prof. Dr. Rafet Eren graduated from Istanbul Faculty of Medicine in 2007. He completed his Internal Medicine specialty training at Marmara University Faculty of Medicine in 2012. In 2018, he became a Hematology subspecialist at Istanbul Training and Research Hospital. In 2019, he was awarded the title of Associate Professor in the field of Hematology. Afterwards, he worked as a faculty member at Başakşehir Çam and Sakura City Hospital, Bozyaka Training and Research Hospital and Istinye University (Istinye University Bahçeşehir and Liv Hospital Vadistanbul) and is currently working at Biruni University Hospital. Dr. Rafet Eren is a member of Turkish Society of Hematology, Hematology Specialty Society and European Society of Hematology and speaks English fluently. He has around 50 publications in national and international refereed journals.

    Scientific Memberships

    • Turkish Hematology Association
    • Hematology Specialty Society
    • Turkish Internal Medicine Specialty Society
    • European Society of Hematology
    •  

    Awards 

    • Young Researcher Award (42nd National Hematology Congress), 2016
    • Special Jury Paper Award (3rd Hematologic Oncology Congress), 2015
    • Paper 3rd Prize (2nd Hematologic Oncology and Bone Marrow Transplantation Symposium), 2016
  • Leia mais
Consulta médica
Preço sob consulta
Info

Gülyüz Öztürk

  • 4.4 Bom 7 avaliações
  • 33 anos de experiência
  • Turquia, Istambul, Acibadem Altunizade Clinic
Quimioterapia para cancro da mama
7374 € - 8675 €
Info

Escolhendo Médico e Clínica: Dicas Internas

Ao selecionar médico ou clínica, considere estes pontos-chave:
Verificar credenciais
Confirmar certificações de entidades como ISAPS, JCI etc.
Analisar taxas de sucesso
Escolha médicos com sólida experiência no tratamento específico.
Ler avaliações de pacientes
Avaliações reais de pacientes Bookimed para conhecer experiências.
Garantir comunicação
Escolher clínicas que oferecem suporte de idioma para tratamento tranquilo.
Perguntar sobre serviços
Verifique se fornecem hospedagem e transferências, e analise custos.
Escolher clínica no exterior pode ser estressante. No Bookimed, com mais de 800K pacientes atendidos, entendemos preocupações. Sabemos encontrar médicos confiáveis, melhores opções de custo-benefício e soluções até para casos complexos. Estamos aqui para orientar em cada etapa.
Yan Matsiivskiy
Chefe da Equipe de Coordenadores Médicos